The drug eluting balloon (DEB) enables administration of antiproliferative drugs directly to diseased arterial walls during minimally invasive angioplasty procedures. DEB treatments are widely used to treat peripheral arterial diseases by preventing restenosis post angioplasty. The global drug eluting balloons market is witnessing significant growth due to rising incidences of cardiovascular diseases worldwide and increasing preference for minimally invasive surgeries over traditional open surgeries. DEBs have emerged as an effective alternative to drug eluting stents as they require lower dosages of antiproliferative drugs and are not confounded by issues related to late stent thrombosis.

The global Drug Eluting Balloon Market is estimated to be valued at Us$ 667.78 Mn in 2023 and is expected to exhibit a CAGR Of 8.6% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in the drug eluting balloon market is the rising demand for paclitaxel coated DEBs. Paclitaxel is one of the most commonly used antiproliferative drugs for drug coated balloons and stents owing to its high efficacy in preventing restenosis. Major players are focusing on developing advanced paclitaxel formulations to improve drug transfer and efficacy. Furthermore, there is increasing research on use of alternative drugs such as sirolimus and everolimus for drug coated balloons. New drug eluting balloon technologies such as nanoparticle drug coating are being researched to optimize local drug transfer and reduce restenosis risk post angioplasty. With growing acceptance of DEB therapies and ongoing innovations, the drug eluting balloons market is expected to witness significant growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The high capital requirements and regulatory barriers pose a threat of medium level for new entrants in the drug eluting balloon market.

Bargaining power of buyers: Buyers have medium level bargaining power in this market due to the availability of alternative treatment options for coronary artery disease.

Bargaining power of suppliers: A few major players dominate the supply side, giving them high bargaining power over buyers.

Threat of new substitutes: Substitutes like drug-coated balloons and drug-eluting stents pose medium level threat due to superior performance attributes.

Competitive rivalry: Being a consolidated market with presence of key global players, the competitive rivalry is high.

Key Takeaways

The Global Drug Eluting Balloon Market Demand is expected to witness high growth over the forecast period.

Regionally, North America is dominating the market currently due to rising prevalence of cardiovascular diseases. However, Asia Pacific is expected to witness fastest growth due to growing healthcare infrastructure and increasing healthcare spending in the region.

Key players:

Key players operating in the drug eluting balloon market are Oracle Corporation (NetSuite Inc.), BatchMaster Software, Columbus Manufacturing, Aquilon Software, CompuTec S.A.(ProcessForce), Datacor Chempax, DESKERA, ERPAG, Fishbowl, Intellect, SAGE GROUP plc, and VAI – Vormittag Associates, Inc. Oracle Corporation (NetSuite Inc.) dominates the market with its technologically advanced offerings.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it